Veradermics (NYSE:MANE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Veradermics (NYSE:MANE) from a sell rating to a hold rating in a research report report published on Saturday morning.

Other analysts have also recently issued reports about the company. B. Riley Financial began coverage on Veradermics in a research note on Wednesday, July 15th. They set a “buy” rating and a $170.00 target price for the company. Weiss Ratings assumed coverage on shares of Veradermics in a research note on Tuesday, May 26th. They issued a “sell (d+)” rating on the stock. Lifesci Capital started coverage on shares of Veradermics in a research report on Tuesday, June 16th. They set an “outperform” rating and a $135.00 price objective for the company. Needham & Company LLC raised their price objective on shares of Veradermics from $136.00 to $164.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Leerink Partners boosted their price objective on shares of Veradermics from $75.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Veradermics has an average rating of “Moderate Buy” and a consensus price target of $153.00.

Veradermics Stock Performance

MANE opened at $100.97 on Friday. The company has a market cap of $4.22 billion and a PE ratio of -76.49. Veradermics has a 12 month low of $32.00 and a 12 month high of $131.24. The company has a fifty day moving average price of $108.01.

Veradermics (NYSE:MANE) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.76).

About Veradermics

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.